DanCann Pharma about the road to commercial breakthrough
DanCann Pharma is active within a growing field of drug development – medical cannabis and therapeutic cannabinoids. The goal is to provide patients in a spectrum of disease indications with safe treatment options without them having to turn to the black market. According to the company, it is facing its commercial breakthrough and to finance the way forward, it is now carrying out an issue of 28.5 million DKK. CEO Jeppe Krog Rasmussen visited BioStock’s studio to tell us more.
Watch the interview with DanCann Pharma’s CEO Jeppe Krog Rasmussen below.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.